title: Prognostic factors for progression of early- and late-stage calcific aortic valve disease in Japanese: the Japanese Aortic Stenosis Study (JASS) Retrospective Analysis.
abstract: Calcific aortic valve disease (CAVD) is the most common etiology of acquired valvular heart disease, and hypertension is a principal underlying disease. The Japanese Aortic Stenosis Study (JASS) Retrospective Analysis is a retrospective observational study to clarify the prognostic factors for progression of CAVD in Japanese. Data from 556 subjects who met the following criteria were analyzed: (1) >or=50 years old; (2) calcification in any aortic valve leaflet or peak aortic jet velocity >or=2 m s(-1) on an echocardiographic study performed between July 2004 and June 2007; and (3) availability of earlier echocardiographic data from within the previous 2-5 years to assess the progression of CAVD. The subjects were divided into two groups according to CAVD severity on the preceding echocardiographic examination. In early-stage subjects with calcification in one or zero leaflets who were without aortic stenosis on the preceding echocardiographic study (n=157), the prognostic factors for progression were the following: (1) no use of angiotensin receptor blockers (ARB) and (2) use of warfarin. In late-stage subjects with calcification in two or three leaflets and/or aortic stenosis on the preceding echocardiographic study (n=399), progression was observed in females and in subjects with low hemoglobin and a concentric left ventricle. There was no relation between medications and changes in CAVD. Prognostic factors for the progression of CAVD were different between the early and late stages. Initiation of ARB treatment during the early stage may be effective, and we should be vigilant about progression of CAVD in patients treated with warfarin.
authors.affiliation: The Center for Advanced Medical Engineering and Informatics, Osaka University, Yamadaoka, Suita, Japan. kazuhiro@medone.med.osaka-u.ac.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshida
authors.forename: Akira
authors.initials: A
authors.lastname: Kisanuki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Hirano
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Ohte
authors.forename: Takashi
authors.initials: T
authors.lastname: Akasaka
authors.forename: Masaaki
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nakatani
authors.forename: Tomohito
authors.initials: T
authors.lastname: Ohtani
authors.forename: Takashi
authors.initials: T
authors.lastname: Sozu
authors.forename: Tohru
authors.initials: T
authors.lastname: Masuyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000925:Anticoagulants / Q000009:adverse effects; D001024:Aortic Valve Stenosis / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D002114:Calcinosis / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control; D018450:Disease Progression; D004452:Echocardiography; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014859:Warfarin / Q000009:adverse effects
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000925:Anticoagulants; D014859:Warfarin